Globus Medical, Inc. Class A Common Stock (GMED)
84.28
-3.10 (-3.55%)
Globus Medical Inc is a medical device company that specializes in the development and commercialization of innovative products for spine surgery
The company focuses on creating solutions that enhance surgical outcomes and improve patient recovery through advanced technologies, including surgical implants, instruments, and robotics. With a robust portfolio, Globus Medical aims to address various spinal conditions and assist healthcare professionals in providing effective treatment options, ultimately striving to elevate the standard of care in spine surgery.
![](https://cdn.benzinga.com/files/images/story/2023/valuestock_image_1.jpeg?width=1200&height=800&fit=crop)
Via Benzinga · February 10, 2025
![](https://www.chartmill.com/images/uploads/Affordable_Growth_500_264px_webp_add6a3aa59.webp)
Based on Fundamental Analysis it can be said that NYSE:GMED is a growth stock which is not overvalued.
Via Chartmill · February 7, 2025
![](https://www.chartmill.com/images/uploads/HGM_Breakout_19d1a7df53.webp)
A fundamental and technical analysis of (NYSEGMED): Exploring GLOBUS MEDICAL INC - A NYSE:GMEDNYSEGMED)
Via Chartmill · January 29, 2025
![](https://www.investors.com/wp-content/uploads/2017/05/IRU77.jpg)
Reflecting its strong growth, on Monday the Relative Strength (RS) Rating for Stryker stock got an upgrade from 70 to 74.
Via Investor's Business Daily · January 13, 2025
![](https://www.investors.com/wp-content/uploads/2019/10/stock-sleep-01-shutter.jpg)
Inspire Medical, which makes innovative apnea relief devices, hit a key performance benchmark as its Relative Strength Rating jumped to 81.
Via Investor's Business Daily · January 8, 2025
![](https://www.chartmill.com/images/uploads/HGM_Breakout_19d1a7df53.webp)
Delving into GLOBUS MEDICAL INC - A (NYSEGMED)'s high Growth Prospects.
Via Chartmill · December 31, 2024
![](https://www.investors.com/wp-content/uploads/2017/05/IRU4.jpg)
Lantheus Holdings sees its Relative Strength Rating reach the 80-plus level.
Via Investor's Business Daily · January 7, 2025
![](https://www.investors.com/wp-content/uploads/2017/05/IRU6.jpg)
On Wednesday, Inari Medical stock received an upgrade to its Relative Strength (RS) Rating, from 65 to 72.
Via Investor's Business Daily · December 11, 2024
![](https://www.chartmill.com/images/uploads/HGM_Breakout_19d1a7df53.webp)
Unlocking the high Growth Potential of GLOBUS MEDICAL INC - A (NYSEGMED).
Via Chartmill · December 10, 2024
![](https://www.investors.com/wp-content/uploads/2017/05/IRU1.jpg)
On Tuesday, Novocure stock got a positive adjustment to its Relative Strength (RS) Rating to 96, up from 73.
Via Investor's Business Daily · December 3, 2024
![](https://cdn.benzinga.com/files/images/story/2024/12/02/Modern-Hospital-And-Communication-Networ.jpeg?width=1200&height=800&fit=crop)
Morgan Stanley upgrades key MedTech stocks, highlighting strong demand and growth potential, while downgrading others amid company-specific challenges.
Via Benzinga · December 2, 2024
![](https://cdn.benzinga.com/files/images/story/2023/analyst_ratings_image_4.png?width=1200&height=800&fit=crop)
Via Benzinga · December 2, 2024
![](https://cdn.benzinga.com/files/images/story/2023/analyst_ratings_image_0.png?width=1200&height=800&fit=crop)
Via Benzinga · October 14, 2024
![](https://www.chartmill.com/images/uploads/Affordable_Growth_500_264px_webp_add6a3aa59.webp)
GLOBUS MEDICAL INC - A (NYSEGMED) stands out as a growth opportunity that won't break the bank.
Via Chartmill · November 7, 2024
![](https://g.foolcdn.com/editorial/images/1/featured-transcript-logo-template-2023-01-12.jpg)
GMED earnings call for the period ending September 30, 2024.
Via The Motley Fool · November 5, 2024
![](https://cdn.benzinga.com/files/images/story/2023/movers_image_1.jpeg?width=1200&height=800&fit=crop)
Via Benzinga · November 6, 2024
![](https://cdn.benzinga.com/files/images/story/2024/11/06/CVS-Health-Corp--CVS.jpeg?width=1200&height=800&fit=crop)
Via Benzinga · November 6, 2024
![](https://www.chartmill.com/images/uploads/Affordable_Growth_500_264px_webp_add6a3aa59.webp)
In the world of growth stocks, NYSE:GMED shines as a value proposition.
Via Chartmill · October 2, 2024
![](https://cdn.benzinga.com/files/images/story/2023/options_image_0.jpeg?width=1200&height=800&fit=crop)
Via Benzinga · September 23, 2024
![](https://www.chartmill.com/images/uploads/Affordable_Growth_500_264px_webp_add6a3aa59.webp)
While growth is established for NYSE:GMED, the stock's valuation remains reasonable.
Via Chartmill · September 11, 2024